Connect with us

Health

Follow-up Sinks Candesartan as Cardioprotection in Breast Cancer – Medscape

The new PRADA findings suggest cardioprotective drugs may not be necessary for all patients during adjuvant breast cancer therapy, the authors say.

Published

on

Article feature image

After a modest early signal of benefit, candesartan cilexetil (Atacand, Cheplapharm) showed no effect on key markers of heart health 2 years after treatment in patients with early-stage breast cancer in the randomized PRADA trial.
The 2015 study was hailed at the time as the largest randomized trial in breast cancer to look at the effects of angiotensin-receptor blockade with candesartan and the -blocker metoprolol, both against placebo, on cardiac dysfunction. The 120 patients received adjuvant…

Click here to view the original article.

You might also like ...

Article feature image
Turkey intensifies COVID-19 vaccination efforts as age lowered | Daily Sabah – Daily Sabah
Article feature image
Too much coffee triples the risk of blinding eye disease. How much is too much? – Ladders
Article feature image
Over-40s in Scotland urged to book second COVID jab as soon as possible – Yahoo Philippines News